In a recent post on June 4th, 2021 the FDA approved a new drug treatment for Weight Loss. The article from the U.S. Food and Drug Administration noted: “Today’s approval offers adults with obesity or overweight a beneficial new treatment option to incorporate into a weight management program,” said John Sharretts, M.D., deputy director of the Division of Diabetes, Lipid Disorders, and Obesity in the FDA’s Center for Drug Evaluation and Research. “FDA remains committed to facilitating the development and approval of additional safe and effective therapies for adults with obesity or overweight.” This new treatment is beyond just promising, it is proven to assist in semaglutide weight loss effectively and safely. On average 70% of American adults are overweight or obese. The health risks associated with being overweight are tremendous. Even losing 5-10% of body weight through dieting and exercise and reduce risk of cardiovascular disease.
In simple terms, Semaglutide, Wegovy or Ozempic improve insulin resistance. This allows calories and fat to be burned, while improving energy. Semaglutide is peptide that works by mimicking a hormone called glucagon-like peptide 1 (GLP-1), which targets an area of the brain that regulates appetite and food intake. By controlling blood sugar spikes and lowering blood sugar, as well as reducing appetite and cravings energy levels are more consistent. Semaglutide is administered by a subcutaneous injection, commonly dosed once weekly. Dosing may be increased after one month if needed.
The safety and effectiveness of Semaglutide have been studied in four 68-week trials. Three were randomized, double-blind, placebo-controlled (including 16-week dose escalation) and one was a randomized, double-blind, placebo-controlled withdrawal study in which patients receiving Semaglutide continued treatment or switched to placebo. In the four studies, more than 2,600 patients received Semaglutide for up to 68 weeks and more than 1,500 patients received a placebo. Semaglutide trial results showed overweight or obese adults receiving weekly semaglutide had a medium weight loss of 14.9% at 68 weeks. In this same study, nearly 70% of participants were able to achieve a 10% weight loss threshold by taking semaglutide. And 32% of participants lost at least 20% of their initial weight.
In other terms, 1 of 3 patients lose 20% of their body weight with the program. Another 1 in 2 lose 15% of their Body Weight! On average, Semaglutide alone can assist in losing 2-4 pounds a week.
Bottom line is— everyone agrees this therapy works wonders for weight loss!
Real Weight Loss results of up to 2-4 pounds per week
Powerful appetite suppressant
Improves Insulin resistance, Burns Fat and Boosts Energy
Safe & Effective Once Weekly Injection
Used in combination with VitalUty Wellness weight loss program for a High Success Rate
FDA Approved for Weight Loss
The most commonly reported side effect is weight loss. However, some have reported nausea, vomiting, diarrhea, stomach pain, or constipation. The rarest risks of serious effects increases in patients with hypoglycemia, kidney problems, and risk of allergic reactions. This medication is ideal for those who are in good health with no kidney or liver issues who wish to lose weight. The medication is not insulin and should not be used if you have type 1 diabetes or develop diabetic ketoacidosis. Consult with the medical professionals at VitalUty Wellness to see if Semaglutide injections are right for you.
Begin your weight loss journey today and let the VitalUty Wellness staff help you reach YOUR weight loss Goals! Call Today 319-693-8800 for pricing or to schedule an appointment.